Lv1
68 积分 2026-02-25 加入
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
17小时前
待确认
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma
12天前
已完结
How I treat plasma cell leukemia
1个月前
已完结
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
1个月前
已完结
BiRD Regimen Followed by Anti‐ BCMA CAR ‐T Cell Immunotherapy as First‐Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single‐Arm, Phase 2 Trial
1个月前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
1个月前
已完结
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies
1个月前
已完结
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease
1个月前
已完结
Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity
1个月前
已完结
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma
2个月前
已完结
皖公网安备34019202002308
